Patented Immunotherapy Candidate
Learn More
Board of Directors Expanded
Learn More
Discovery to Science-Led Public Company
Learn More
CEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Learn More
Previous
Next
Patented Immunotherapy Candidate
Learn More
Board of Directors Expanded
Learn More
The Journey from Discovery to IPO
Learn More
CEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Learn More
Previous
Next
Patented Immunotherapy Candidate
Board of Directors Expanded
The Journey from Discovery to IPO
CEO Dwain Irvin, PhD, MPH, Attended Recent BioTech Conference
Previous
Next

Our patented approach, TLR-AD1, bolsters the body’s own immune system through cellular training; resulting in cancer-fighting cells increasing in number and intelligence.

NovAccess Global CEO Dwain Irvin, Ph.D., MPH, Interviewed by Don Baillargeon

With TLR-AD1, we will provide Novel Access to the Global market.

Join Us